Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. stent thrombosis
Show results for
Products
Applications

Companies

News
Articles

Refine by
Date

  • Older

Stent Thrombosis Articles & Analysis

4 news found

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

FXIa inhibitors that selectively modulate coagulation through FXIa inhibition could represent a fundamentally new approach to antithrombotic treatment, as they prevent thrombosis yet still allow haemostatic clots that are crucial to repair injury. ...

ByBayer AG


Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

The components of target lesion revascularization (TLF) were low in both women and men and numerically favored females, including target vessel-myocardial infarction (8.5 percent vs 9.7 percent), target lesion revascularization (2.9 percent vs 4.2 percent) and stent thrombosis (0 percent vs 1.2 percent). “Given the established safety profile of IVL and the ...

ByShockwave Medical Inc.


Medinol Completes Enrollment of EluNIR-HBR Study

Medinol Completes Enrollment of EluNIR-HBR Study

The Primary endpoint of the EluNIR-HBR study is a composite of cardiac death, myocardial infarction or stent thrombosis at 1 year (ARC definite and probable). “The EluNIR-HBR study will allow us to determine the optimal duration of DAPT following PCI among this group of complex patients”, said Medinol’s Chief Scientific Officer, Yoram Richter, ...

ByMedinol


FFR-SEARCH Shows Clear Trend Towards Major Adverse Cardiac Events with Lower FFR

FFR-SEARCH Shows Clear Trend Towards Major Adverse Cardiac Events with Lower FFR

” Although statistical significance was not shown at the two-year primary endpoint, additional follow-on subgroup analysis, specifically for myocardial infarction (MI) and stent thrombosis events, may provide additional hypothesis-generating insights. ...

ByACIST Medical Systems

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT